Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Contributed by: PR Newswire

Tags

BIORETEC-HEALTHCARE

More Like This

Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma Screw product portfolio, allowing market launch in Europe

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures

Inside information: Bioretec's European market authorization for RemeOs trauma screw has proceeded to expert panel evaluation, the approval is estimated during the Q2 2024

CE Mark Approval for RemeOs™ Trauma Screw Product Group, featuring four product lines with over 200 individual products, drives global expansion for Bioretec

Inside information: Bioretec estimates that the approval of the European market authorization for the biodegradable RemeOs™ trauma screw will move to the first quarter of 2024

The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market